Decode Age, a Bengaluru-based sequencing laboratory and supplement company, combines gut microbiome testing with the sale of compounds including NMN, resveratrol, spermidine, and alpha-ketoglutarate, marketed as bioage interventions. The startup has grown to ₹11.9 crore in annual revenue with recent institutional funding, though human efficacy data for these compounds remains limited.
Key Points
- Gut microbiome sequencing paired with multi-omics analysis identifies microbial composition and biom
- Supplements represent 93% of revenue; compounds target cellular energy and metabolic markers
- Animal and laboratory evidence exists; human longevity efficacy remains unestablished
Longevity Analysis
The business model reflects a broader market trend toward consumer biomarker testing and targeted supplementation based on microbial and genomic data. While gut microbial composition genuinely influences host metabolism, immune function, and systemic inflammation, the translation from animal models to sustained human health benefit requires rigorous validation. The compounds marketed—NMN, resveratrol, spermidine, and alpha-ketoglutarate—operate through cellular energy pathways and stress response mechanisms in controlled settings, but their long-term impact on human aging trajectories at typical supplemental doses remains uncertain. The company's growth suggests consumer demand for personalized biological-age assessment, though practitioners evaluating such services should distinguish between microbiome insight (actionable through diet and lifestyle) and supplement efficacy claims that lack established human trial data.
Original published by LT Wire.